8-K Announcements
6Material company update
Jun 16, 2023·SEC
Material company update
Jun 5, 2023·SEC
Material company update
May 11, 2023·SEC
Chemomab Therapeutics Ltd.(CMMB)Earnings, Financials & Key Ratios
CMMB•NASDAQ
$1.59
Price updated Jun 27, 2026
AboutChemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.Show more
- Revenue$0
- EBITDA-$9M+35.3%
- Net Income-$9M+35.5%
- EPS (Diluted)-1.42+54.5%
- ROE-69.54%+23.9%
CMMB Price & Volume
Chemomab Therapeutics Ltd. (CMMB) stock price & volume — 10-year historical chart
Loading chart...
CMMB Growth Metrics
Chemomab Therapeutics Ltd. (CMMB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM35.41%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM58.76%
Return on Capital
10 Years-169.92%
5 Years-71.08%
3 Years-87.74%
Last Year-73.37%
Peers Comparison
Key metrics vs top competitors for Chemomab Therapeutics Ltd. (CMMB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.59 | $9.79M | -1.12 | — | — | -69.54% | — | |
| $74.96 | $8.89B | 29.28 | 37.55% | 23.13% | 126.27% | — | |
| $5.55 | $1.36B | -21.35 | 22.09% | -13.58% | -38.11% | — | |
| $10.02 | $524.58M | -2.21 | -92.84% | -260.92% | -49.88% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $25.32 | $4.34B | 11.06 | 11.87% | 34.3% | 35.65% | — |
Compare CMMB vs Peers
Chemomab Therapeutics Ltd. (CMMB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CMMB SEC Filings & Documents
Chemomab Therapeutics Ltd. (CMMB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CMMB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CMMB Frequently Asked Questions
Chemomab Therapeutics Ltd. (CMMB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is CMMB profitable?
Chemomab Therapeutics Ltd. (CMMB) reported a net loss of $9.0M for fiscal year 2025.
Dividend & Returns
What is CMMB's return on equity?
Chemomab Therapeutics Ltd. (CMMB) has a return on equity (ROE) of -69.5%. Negative ROE indicates the company is unprofitable.
What is Chemomab Therapeutics Ltd.'s free cash flow?
Chemomab Therapeutics Ltd. (CMMB) had negative free cash flow of $11.2M in fiscal year 2025, likely due to heavy capital investments.